MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Botulinum toxin: Clinical applications: dystonia"

  • 2019 International Congress

    Classification of idiopathic cervical dystonia: an observational study

    P. Tater, N. Sarma, S. Pandey (New Delhi, India)

    Objective: The aim of our study was to classify patients with idiopathic cervical dystonia who had never been injected botulinum toxin. Background: Idiopathic cervical dystonia…
  • 2019 International Congress

    High Dose Botulinum Toxin Therapy: Safety, Benefit and Endurance of Efficacy

    S. Chiu, B. Patel, M. Burns, J. Legacy, A. Shukla, A. Ramirez-Zamora, W. Deeb, I. Malaty (Gainesville, FL, USA)

    Objective: To assess safety, therapeutic response and long-term benefit of higher dose Onabotulinum toxin A (OnaA). Background: Botulinum toxin therapy is a powerful tool for…
  • 2019 International Congress

    Effect of Botulinum Toxin Treatment on Cervical Dystonia

    S. Tomic, M. Tomasevic, D. Hardi, T. Gilman Kuric, Z. Popovic (Osijek, Croatia)

    Objective: To find out influence of botulinum toxin (BonT) treatment on improvement of motor symptoms and pain.To find out influence of botulinum toxin (BonT) treatment…
  • 2019 International Congress

    Botulinum toxin type A therapy in a movement disorders unit: a 23-year experience.

    M. Velez, C. Cosentino, L. Torres (Lima, Peru)

    Objective: To update the experience with botulinum toxin type A therapy at the Unidad de Movimientos Involuntarios (UMI) of Instituto Nacional de Ciencias Neurologicas (INCN)-Lima,…
  • 2019 International Congress

    Management of poor response to Botulinum toxin in cervical dystonia: a multicentre audit

    H. Tucker, F. Osei-Poku, D. Ashton, R. Lally, J. Alty, C. Kobylecki (Salford, United Kingdom)

    Objective: To audit the management of cervical dystonia patients with secondary poor responsiveness to BoNT in two regional U.K. neuroscience centres against the British Neurotoxin…
  • 2018 International Congress

    Prevalence and Correlates of Anxiety & Depression in Cervical Dystonia

    M. Al Hussona, I. Ndukwe, S. O'Riordan, R. Beck, R. Reilly, M. Hutchinson (Dublin, Ireland)

    Objective: Our aim was to assess the prevalence and severity of mood disorder in our Cervical Dystonia population attending the botulinum toxin clinic and to…
  • 2018 International Congress

    Assessment of cognitive functions, depression-anxiety scales and quality of life in patients and their relatives with Cervical Dystonia and Botulinum Toxin Treatment

    D. Ceylan, S. Erer, M. Zarifoglu, N. Turkes, A. Demiralay (Bursa, Turkey)

    Objective: In this study, we investigated the psychiatric comorbid disorders and quality of life issues such as cognitive dysfunction accompanied by cervical dystonia and accompanying…
  • 2018 International Congress

    How much does botulinum toxin injection interval impact upon patient satisfaction in the routine treatment of cervical dystonia?

    T. Chung, D. Charles, C. Colosimo, V. Misra, P. Maisonobe, S. Om (São Paulo, Brazil)

    Objective: Evaluate the impact of injection interval on satisfaction with botulinum toxin-A (BoNT-A) treatment in cervical dystonia (CD) patients who have been treated for 1…
  • 2018 International Congress

    Who uses guidance techniques for abobotulinumtoxinA injections in the routine management of cervical dystonia?

    V. Misra, R. Trosch, P. Maisonobe, S. Om (London, United Kingdom)

    Objective: Describe the use of injection guidance techniques in different cervical dystonia (CD) patient populations treated in routine practice. Background: The use of injection guidance…
  • 2018 International Congress

    Duration of response with abobotulinumtoxinA in cervical dystonia: Patient distribution results from two open label extension studies

    R. Hauser, D. Truong, M. Jog, D. Grimes, P. Picaut, A. Mann (Tampa, FL, USA)

    Objective: To report patient distribution data for duration of response with abobotulinumtoxinA (aboBoNT-A; Dysport®) from two open-label (OL) studies in patients with cervical dystonia (CD).…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 21
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley